Literature DB >> 9330547

Current antiretroviral therapy: an overview.

R M Gulick1.   

Abstract

Advances in the understanding of human immunodeficiency virus (HIV) pathogenesis, clinical assessment with viral load testing and the availability of potent combination antiretroviral therapy regimens have led to significant changes in options for HIV-infected patients. From the first approved antiretroviral agent, zidovudine (AZT), through two-drug nucleoside analogue regimens, to the current three-drug combination regimens with protease inhibitors, both the benefits of therapy and the complexities of therapy continue to increase. With the clinical benefits come associated lifestyle constraints and, thus, the impact and assessment of potent antiretroviral therapy on patient quality of life (QoL) becomes increasingly complicated.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9330547     DOI: 10.1023/a:1018447829842

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   3.440


  25 in total

Review 1.  HIV viral load markers in clinical practice.

Authors:  M S Saag; M Holodniy; D R Kuritzkes; W A O'Brien; R Coombs; M E Poscher; D M Jacobsen; G M Shaw; D D Richman; P A Volberding
Journal:  Nat Med       Date:  1996-06       Impact factor: 53.440

2.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

Authors:  S M Hammer; K E Squires; M D Hughes; J M Grimes; L M Demeter; J S Currier; J J Eron; J E Feinberg; H H Balfour; L R Deyton; J A Chodakewitz; M A Fischl
Journal:  N Engl J Med       Date:  1997-09-11       Impact factor: 91.245

3.  Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.

Authors:  R M Gulick; J W Mellors; D Havlir; J J Eron; C Gonzalez; D McMahon; D D Richman; F T Valentine; L Jonas; A Meibohm; E A Emini; J A Chodakewitz
Journal:  N Engl J Med       Date:  1997-09-11       Impact factor: 91.245

4.  Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee.

Authors: 
Journal:  Lancet       Date:  1996-08-03       Impact factor: 79.321

5.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors.

Authors:  J H Condra; W A Schleif; O M Blahy; L J Gabryelski; D J Graham; J C Quintero; A Rhodes; H L Robbins; E Roth; M Shivaprakash
Journal:  Nature       Date:  1995-04-06       Impact factor: 49.962

6.  Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS.

Authors:  L D Saravolatz; D L Winslow; G Collins; J S Hodges; C Pettinelli; D S Stein; N Markowitz; R Reves; M O Loveless; L Crane; M Thompson; D Abrams
Journal:  N Engl J Med       Date:  1996-10-10       Impact factor: 91.245

7.  A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.

Authors:  S M Hammer; D A Katzenstein; M D Hughes; H Gundacker; R T Schooley; R H Haubrich; W K Henry; M M Lederman; J P Phair; M Niu; M S Hirsch; T C Merigan
Journal:  N Engl J Med       Date:  1996-10-10       Impact factor: 91.245

8.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.

Authors:  D D Ho; A U Neumann; A S Perelson; W Chen; J M Leonard; M Markowitz
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

9.  Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.

Authors:  A C Collier; R W Coombs; D A Schoenfeld; R L Bassett; J Timpone; A Baruch; M Jones; K Facey; C Whitacre; V J McAuliffe; H M Friedman; T C Merigan; R C Reichman; C Hooper; L Corey
Journal:  N Engl J Med       Date:  1996-04-18       Impact factor: 91.245

10.  Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee.

Authors: 
Journal:  Lancet       Date:  1994-04-09       Impact factor: 79.321

View more
  6 in total

1.  BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents.

Authors:  B S Robinson; K A Riccardi; Y F Gong; Q Guo; D A Stock; W S Blair; B J Terry; C A Deminie; F Djang; R J Colonno; P F Lin
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

2.  Psychometric evaluation of the functional assessment of HIV Infection (FAHI) questionnaire and its usefulness in clinical trials.

Authors:  Muriel Viala-Danten; Dominique Dubois; Hélène Gilet; Silas Martin; Katrien Peeters; David Cella
Journal:  Qual Life Res       Date:  2010-05-28       Impact factor: 4.147

3.  In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632.

Authors:  Y F Gong; B S Robinson; R E Rose; C Deminie; T P Spicer; D Stock; R J Colonno; P F Lin
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

4.  Health-related quality of life and virologic outcomes in an HIV clinic.

Authors:  S A Call; J C Klapow; K E Stewart; A O Westfall; A P Mallinger; R A DeMasi; R Centor; M S Saag
Journal:  Qual Life Res       Date:  2000       Impact factor: 4.147

5.  X-ray crystal structures of human immunodeficiency virus type 1 protease mutants complexed with atazanavir.

Authors:  Herbert E Klei; Kevin Kish; Pin-Fang M Lin; Qi Guo; Jacques Friborg; Ronald E Rose; Yaqun Zhang; Valentina Goldfarb; David R Langley; Michael Wittekind; Steven Sheriff
Journal:  J Virol       Date:  2007-05-30       Impact factor: 5.103

6.  Economic methods for measuring the quality of life associated with HIV infection.

Authors:  A M Bayoumi; D A Redelmeier
Journal:  Qual Life Res       Date:  1999-09       Impact factor: 3.440

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.